logo-loader
viewMajestic Wine PLC

Majestic Wine drops six bottles minimum order requirement

Who saw this coming? Just about everybody, and market reaction has been lukewarm.

Winebottles.jpg
I'll drink to that: ordering fewer than six bottles is now an option

Majestic Wine (LON:MJW) is looking to restore some body to its top line growth by abandoning its six bottle minimum purchase requirement.

With effect from Tuesday, 27 October, a new pricing strategy will be in force at Majestic, both online and in its bricks & mortar retail estate.

The move is intended to make the shopping experience simpler and easier, both for new and existing customers, although the company immediately made things more complicated by announcing a special Christmas offer that only applies if customers mix any six wines and spirits in their purchase.

"Our customers were telling us that they wanted simpler, clearer pricing, and an end to the six bottle minimum,” said Rowan Gormley, who took over as chief executive officer in April of this year, shortly after Naked Wines, the company he founded, was acquired by Majestic.

“This new structure is part of our wider plan to reposition Majestic Wine to become the go-to destination for the best quality wines at the best prices. There are now no barriers to shopping at Majestic, the pricing structure is very straightforward and I'm sure our customers will see this as a great move," he asserted.

Shares in Majestic Wine were down 1.1%, under-performing the market, at 351p in early trading.

Quick facts: Majestic Wine PLC

Price: 214.5 GBX

AIM:WINE
Market: AIM
Market Cap: £156.21 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Medicenna Therapeutics completes Phase 2B study on cancer drug mdna55

Medicenna Therapeutics (TSE: MDNA) CFO Elizabeth Williams joined Steve Darling from Proactive Vancouver at LD MIcrocap Conference in Vancouver with news about their lead drug mdma55. Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and commercialization...

8 hours, 47 minutes ago

RNS

Completion of disposal of Majestic Wine

23 hours, 19 minutes ago

Holding(s) in Company

2 weeks ago

Holding(s) in Company

2 weeks, 1 day ago

Director/PDMR Shareholding

2 weeks, 5 days ago

Director/PDMR Shareholding

2 weeks, 5 days ago

Half-year Report

2 weeks, 6 days ago

Holding(s) in Company

4 weeks ago

2 min read